S. Jimenez-Cabrera

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

C. Martínez, R. García-Sanz, E. Domingo-Domènech, 2019 .

Dysgeusia as an adverse reaction to praziquantel

V. Velasco-Tirado, M. Belhassen-García, I. Novo-Veleiro, 2012, Drug and chemical toxicology.

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

C. Martínez, R. García-Sanz, E. Domingo-Domènech, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.